Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Montalescot

Showing results (31-40 of 143) with videos related to

Pageof 15
Sort By:
Presse Medicale (Paris, France : 1983)|November 17, 2001
[Fibrinogen: a cardiovascular risk factor]J L Colas, G Montalescot, C Tribouilloy
International Journal of Clinical Pharmacology and Therapeutics|December 31, 2004
Revascularization strategies in acute myocardial infarction: a meta-analysisA Bouzamondo, T Damy, G Montalescot, et al.
Archives Des Maladies Du Coeur Et Des Vaisseaux|May 20, 1998
[Use of abciximab during coronary angioplasty]F Philippe, G Montalescot, G Drobinski, et al.
Archives Des Maladies Du Coeur Et Des Vaisseaux|April 1, 1988
[Development of left ventricular function following aortic valve replacement]G Montalescot, G Drobinski, D Thomas, et al.
Pharmacoeconomics|September 30, 2000
Economic evaluation of enoxaparin sodium versus heparin in unstable angina. A French sub-study of the ESSENCE trialB Detournay, X Huet, F Fagnani, et al.
Circulation|October 8, 2003
Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysisM Dalby, A Bouzamondo, P Lechat, et al.
European Heart Journal|August 26, 1998
Fibrinogen as a risk factor for coronary heart diseaseG Montalescot, J P Collet, R Choussat, et al.
Drugs|January 1, 1990
Haemodynamic effects of intravenous urapidil in patients with advanced left ventricular failureG Drobinski, G Montalescot, J M Fossier, et al.
Annales De Cardiologie Et D'Angeiologie|March 1, 1993
[Effects of urapidil by intravenous injection on pulmonary circulation and cardiac function in left ventricular failure]G Drobinski, G Montalescot, J M Fossier, et al.
Therapie|March 1, 1990
[Hemodynamic effects of quinacainol administered via an intravenous route. Study in patients with normal left ventricular function]G Drobinski, G Montalescot, N Moussallem, et al.
Pageof 15

Showing results (31-40 of 143) with videos related to

Sort By:
Pageof 15
Presse Medicale (Paris, France : 1983)|November 17, 2001
[Fibrinogen: a cardiovascular risk factor]J L Colas, G Montalescot, C Tribouilloy
International Journal of Clinical Pharmacology and Therapeutics|December 31, 2004
Revascularization strategies in acute myocardial infarction: a meta-analysisA Bouzamondo, T Damy, G Montalescot, et al.
Archives Des Maladies Du Coeur Et Des Vaisseaux|May 20, 1998
[Use of abciximab during coronary angioplasty]F Philippe, G Montalescot, G Drobinski, et al.
Archives Des Maladies Du Coeur Et Des Vaisseaux|April 1, 1988
[Development of left ventricular function following aortic valve replacement]G Montalescot, G Drobinski, D Thomas, et al.
Pharmacoeconomics|September 30, 2000
Economic evaluation of enoxaparin sodium versus heparin in unstable angina. A French sub-study of the ESSENCE trialB Detournay, X Huet, F Fagnani, et al.
Circulation|October 8, 2003
Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysisM Dalby, A Bouzamondo, P Lechat, et al.
European Heart Journal|August 26, 1998
Fibrinogen as a risk factor for coronary heart diseaseG Montalescot, J P Collet, R Choussat, et al.
Drugs|January 1, 1990
Haemodynamic effects of intravenous urapidil in patients with advanced left ventricular failureG Drobinski, G Montalescot, J M Fossier, et al.
Annales De Cardiologie Et D'Angeiologie|March 1, 1993
[Effects of urapidil by intravenous injection on pulmonary circulation and cardiac function in left ventricular failure]G Drobinski, G Montalescot, J M Fossier, et al.
Therapie|March 1, 1990
[Hemodynamic effects of quinacainol administered via an intravenous route. Study in patients with normal left ventricular function]G Drobinski, G Montalescot, N Moussallem, et al.
Pageof 15